A U.K. startup and a Japanese pharmaceutical company have jointly developed the first artificial intelligence (AI) derived pharmaceutical, according to reports.

Exscientia and Sumitomo Dainippon Pharma used drug discovery technology called Centaur Chemist to develop molecule DSP-1181, a serotonin 5-HTIA receptor agonist for treating obsessive compulsive disorder (OCD), which is thought to develop when there is a serotonin imbalance in the brain.

To develop the molecule, algorithms sorted through various compounds in an enormous database of different parameters, including genetic factors. The AI reportedly sped up the process by sorting through billions of decisions required for drug selection.

The new molecule is set to undergo human trials in Japan. Such a feat, which traditionally takes five years to achieve, was accomplished in roughly 12 months using the AI. If the trials are successful, human trials could lead to even more global tests of the pharmaceutical. Likewise, Exscientia and Sumitomo Dainippon Pharma are also working to develop AI-designed pharmaceuticals to treat cardiovascular disease and cancer.

This is not AI’s first foray into the healthcare field. AI has been applied to a host of healthcare-related applications including detecting diabetic retinopathy, predicting heart attacks and even predicting premature death.